Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-04
2000-08-01
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514446, 514448, A61K 3138
Patent
active
060967811
ABSTRACT:
This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I: ##STR1##
REFERENCES:
patent: 4418068 (1983-11-01), Jones
patent: 4588484 (1986-05-01), Justice, Jr. et al.
patent: 5389670 (1995-02-01), Fontana
patent: 5391557 (1995-02-01), Cullinan et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5464845 (1995-11-01), Black et al.
patent: 5488058 (1996-01-01), Palkowitz
patent: 5492922 (1996-02-01), Palkowitz
patent: 5510357 (1996-04-01), Palkowitz
patent: 5514703 (1996-05-01), Carlson et al.
patent: 5514704 (1996-05-01), Carlson et al.
patent: 5532382 (1996-07-01), Carlson et al.
patent: 5534526 (1996-07-01), Cullinan et al.
patent: 5641790 (1997-06-01), Draper
patent: 5646137 (1997-07-01), Black et al.
patent: 5670514 (1997-09-01), Audia et al.
patent: 5686476 (1997-11-01), May
patent: 5723474 (1998-03-01), Palkowitz
patent: 5731342 (1998-03-01), Cullinan et al.
patent: 5747510 (1998-05-01), Draper
patent: 5760061 (1998-06-01), Fontana
patent: 5811120 (1998-09-01), Gibson et al.
patent: 5972383 (1999-10-01), Gibson et al.
Draper et al., "effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism Healthy Postmemopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection fro Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist",Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolik et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am.Soc. Bone & Min. Res., Tampa Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Antiestrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene and Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TCGB-3 Expression in Bone;" Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series; "The Endocrine Society, Abstract 1982.
Black et al., Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice, Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109; 1981, 987-989.
Black, L.J. "Biological Actions and Binding Properties of a New Estrogen Antagosist LY117018," In: Hormone Antagonists, 129-82, 1982, (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black, et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New Benzothiophene Derived Antiestrogen, Life Sciences, 32:1983, 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 too its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl) ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22:1979, 962-966.
Black et al., Antiestrogens 2, Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med.Chem. 27(8), 1984, 1057-166.
Health News Daily, vol. 9, No. 239, p. 1--Dec. 11, 1997.
Palkowitz, et al., Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperdinyl)ethoxy]phenoxy]-2-(4 hydrooxyphenyl)]benzo[b]thiophene: A Novel, Highly Potent, Selective Estrogen Receptor Modulator, J. Med. Chem., 40(10), 1407-1416 (1997).
Capozzi, et al., Phthalimidesulfenyl Chloride; Part VII: Synthesis of 2-Substituted 3-Chlorobenzo[b]thio-[jemes amd Related Heteroaromatics, Synthesis, (5) 521-525 (1994).
Khovidhunkit, et al., "Clinical Effects of Raloxifene Hydrochloride in Women", Ann Intern Med, 130:431-9 (1999).
Delmas et al., Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women, N. Engl J. Med., 337:1641-7 (1997).
Walsh, et al., "Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women", JAMA 279:1445-51 (1998).
Cummings, et al., "The Effect of Raloxcifene on Risk of Breast Cancer in Postmenopausal Women" JAMA, 281:2189-97 (1999).
Ettinger, et al., "Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial" J. Am Med Assoc. 282:637-45 (1999).
Nickelsen, et al., "Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator: Safety Assessment of Effects on Cognitive Function and Mood in Postmenopausal Women" Psychoneuroendocrinology, 24:115-28 (1999).
Boudreaux William R.
Criares Theodore J.
Eli Lilly and Company
Kim Jennifer
Sales James J.
LandOfFree
2-arylbenzo[B]thiophenes useful for the treatment of estrogen de does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-arylbenzo[B]thiophenes useful for the treatment of estrogen de, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-arylbenzo[B]thiophenes useful for the treatment of estrogen de will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664506